See more : Nittoc Construction Co., Ltd. (1929.T) Income Statement Analysis – Financial Results
Complete financial analysis of Marinomed Biotech AG (MARI.VI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marinomed Biotech AG, a leading company in the Biotechnology industry within the Healthcare sector.
- American Well Corporation (AMWL) Income Statement Analysis – Financial Results
- Universal Music Group N.V. (UNVGY) Income Statement Analysis – Financial Results
- The Mercantile Investment Trust plc (MRC.L) Income Statement Analysis – Financial Results
- NeuroSense Therapeutics Ltd. (NRSNW) Income Statement Analysis – Financial Results
- Valor Resources Limited (VOYRF) Income Statement Analysis – Financial Results
Marinomed Biotech AG (MARI.VI)
About Marinomed Biotech AG
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.18M | 11.28M | 11.63M | 8.12M | 6.14M | 4.67M | 4.81M | 2.61M | 2.22M |
| Cost of Revenue | 8.04M | 9.14M | 10.20M | 8.77M | 6.66M | 4.83M | 4.16M | 2.43M | 1.29M |
| Gross Profit | 1.14M | 2.14M | 1.42M | -641.70K | -512.30K | -165.45K | 651.42K | 176.16K | 927.35K |
| Gross Profit Ratio | 12.45% | 18.98% | 12.25% | -7.90% | -8.34% | -3.55% | 13.54% | 6.75% | 41.86% |
| Research & Development | 0.00 | 6.91M | 7.50M | 5.94M | 4.78M | 2.93M | 2.19M | 2.66M | 0.00 |
| General & Administrative | 1.02M | 1.39M | 1.06M | 1.07M | 1.16M | 2.29M | 555.37K | 463.40K | 642.76K |
| Selling & Marketing | 246.70K | 298.50K | 396.20K | 290.10K | 180.80K | 107.53K | 108.77K | 87.81K | 43.03K |
| SG&A | 1.27M | 1.69M | 1.45M | 1.36M | 1.34M | 2.39M | 664.14K | 551.21K | 685.79K |
| Other Expenses | 5.01M | 0.00 | 0.00 | -2.40K | -1.20K | 8.16K | 5.42K | 4.09K | -10.11K |
| Operating Expenses | 6.27M | 7.01M | 5.57M | 5.22M | 5.78M | 5.00M | 2.33M | 1.72M | 2.17M |
| Cost & Expenses | 14.31M | 16.15M | 15.77M | 13.99M | 12.44M | 9.83M | 6.49M | 4.16M | 3.46M |
| Interest Income | 16.90K | 200.00 | -59.50K | 53.10K | 70.30K | 10.81K | 32.13K | 31.98K | 29.84K |
| Interest Expense | 2.49M | 2.51M | 1.51M | 713.60K | 665.40K | 2.99M | 953.76K | 445.98K | 185.79K |
| Depreciation & Amortization | 678.20K | 669.70K | 608.90K | 428.40K | 327.20K | 236.76K | 202.58K | 183.52K | 163.05K |
| EBITDA | -3.62M | -3.21M | -3.58M | -4.86M | -6.22M | -10.36M | -1.22M | -1.34M | -1.06M |
| EBITDA Ratio | -39.45% | -28.49% | -30.76% | -59.87% | -95.74% | -68.53% | -29.89% | -51.52% | -46.99% |
| Operating Income | -5.13M | -4.91M | -4.14M | -5.82M | -6.21M | -5.14M | -1.64M | -1.53M | -1.21M |
| Operating Income Ratio | -55.85% | -43.58% | -35.64% | -71.59% | -101.07% | -110.17% | -34.05% | -58.51% | -54.48% |
| Total Other Income/Expenses | -1.66M | -1.48M | -1.55M | -190.70K | -1.00M | -6.95M | -738.40K | -447.19K | -204.85K |
| Income Before Tax | -6.79M | -6.39M | -5.69M | -6.01M | -7.21M | -12.09M | -2.38M | -1.97M | -1.41M |
| Income Before Tax Ratio | -73.95% | -56.68% | -48.97% | -73.93% | -117.37% | -259.16% | -49.40% | -75.65% | -63.73% |
| Income Tax Expense | 4.00K | 6.80K | 197.10K | 3.50K | 4.40K | 3.50K | 1.75K | 1.75K | 1.75K |
| Net Income | -6.79M | -6.40M | -5.89M | -6.01M | -7.22M | -12.10M | -2.38M | -1.97M | -1.41M |
| Net Income Ratio | -73.99% | -56.74% | -50.67% | -73.98% | -117.44% | -259.24% | -49.43% | -75.72% | -63.81% |
| EPS | -4.48 | -4.27 | -3.99 | -4.09 | -5.09 | -12.10 | -1.53 | -1.27 | -0.91 |
| EPS Diluted | -4.48 | -4.27 | -3.99 | -4.09 | -5.09 | -12.10 | -1.53 | -1.27 | -0.91 |
| Weighted Avg Shares Out | 1.52M | 1.50M | 1.48M | 1.47M | 1.42M | 1.00M | 1.55M | 1.55M | 1.55M |
| Weighted Avg Shares Out (Dil) | 1.52M | 1.50M | 1.48M | 1.47M | 1.42M | 1.00M | 1.55M | 1.55M | 1.55M |
Source: https://incomestatements.info
Category: Stock Reports